Navigating EHDS & GDPR: A Guide for Non-EU Health Tech Companies

Navigating EHDS & GDPR: A Guide for Non-EU Health Tech Companies ================================================================ For non-EU based medical device and digital health organizations, the establishment of the European Health Data Space (EHDS) introduces a new layer of complexity on top of existing General Data Protection Regulation (GDPR) obligations. While the role of an EU-based representative under GDPR Article 27 is established for handling data subject inquiries and liaising with supervisory authorities, the EHDS framework significantly evolves the responsibilities and required competencies of this role. The EHDS transforms the EU representative from a primarily GDPR-focused compliance function into a more specialized liaison for the broader European health data landscape. This shift necessitates a deeper understanding of health data regulations, new data governance bodies, and the principles of secondary data use for research and innovation. Non-EU companies, particularly those in the Software as a Medical Device (SaMD) space, must now re-evaluate their representative's capabilities to ensure they can navigate this new, interconnected ecosystem. ### Key Points * **Expanded Role Beyond GDPR:** The EHDS framework expands the EU representative's duties beyond managing data subject rights and DPA communication. The role now includes liaising with new entities, such as Health Data Access Bodies (HDABs), regarding the secondary use of health data. * **New Stakeholder Engagement:** Representatives must be competent in interacting with HDABs, which act as gatekeepers for accessing health data for research and innovation. This requires a different skill set than traditional interactions with Data Protection Authorities (DPAs). * **Critical Competency Shift:** Expertise in GDPR alone is no longer sufficient. An effective representative must now possess a nuanced understanding of the EHDS, EU health regulations (like MDR/IVDR), and the technical and ethical considerations of secondary data use. * **Impact on Compliance Documentation:** Non-EU companies must update key documents, including their Records of Processing Activities (ROPA) and Data Processing Agreements (DPA), to explicitly account for data processing related to secondary use under the EHDS. * **Strategic Representative Selection:** Choosing a representative requires a more rigorous vetting process. Companies must assess a provider's specific experience with health data, the EHDS framework, and their procedural readiness for managing inquiries from HDABs. * **Proactive Governance is Essential:** To prepare for the EHDS, non-EU companies should work with their representative to establish robust internal governance structures that anticipate new data access, security, and interoperability requirements. ## Understanding the Shift: From GDPR Compliance to a Broader Health Data Ecosystem To appreciate the impact of the EHDS, it is essential to first understand the traditional role of the GDPR representative and how the new framework builds upon it. ### The Traditional Role of the GDPR Article 27 Representative Under GDPR, any non-EU organization that processes the personal data of EU residents in relation to offering goods/services or monitoring their behavior must appoint an EU-based representative. The core responsibilities of this Article 27 Representative include: * **Point of Contact:** Serving as the primary contact for EU-based Data Protection Authorities (DPAs) and for individuals (data subjects) regarding all issues related to data processing. * **Documentation:** Maintaining a copy of the organization's Record of Processing Activities (ROPA) and making it available to DPAs upon request. * **Facilitation:** Acting on behalf of the non-EU company to facilitate communication and ensure compliance with GDPR obligations, particularly regarding data subject rights (e.g., access, rectification, erasure). This role has traditionally been focused on the *primary use* of data—the initial purpose for which the data was collected—and ensuring the rights of individuals are protected within that context. ### How the EHDS Introduces a New Paradigm: Secondary Use of Health Data The EHDS aims to create a unified market for electronic health data, empowering citizens with control over their data while enabling its use for public good. A core component of this is facilitating the **secondary use of electronic health data**. This refers to processing health data for purposes other than the primary reason it was collected (i.e., treating a patient). Secondary uses include: * Scientific research * Development and innovation activities * Policy-making and public health statistics * Personalized medicine algorithm training To govern this, the EHDS introduces new entities called **Health Data Access Bodies (HDABs)**. These national bodies will be responsible for granting, refusing, or amending data access permits to researchers, institutions, and companies seeking to use health data for secondary purposes. This creates a new regulatory pathway and a new set of stakeholders with whom non-EU companies must interact. ## Evolving Responsibilities of the EU Representative Under EHDS The introduction of HDABs and the focus on secondary data use directly impacts the day-to-day responsibilities of the EU representative for a health tech company. ### New Communication and Liaison Duties The representative's role as a liaison expands significantly. While they must still be prepared to engage with DPAs on GDPR compliance, they will now also be the likely point of contact for HDABs. Inquiries from an HDAB will differ fundamentally from those from a DPA. * **DPA Inquiry:** Typically focuses on the legal basis for processing, data security measures, and the handling of a data subject complaint. It is a question of *legal compliance*. * **HDAB Inquiry:** More likely to focus on the specifics of a data set requested for secondary use. This could include verifying the data minimization measures applied, confirming the security of the processing environment, or clarifying technical details about the data's structure and origin. It is a question of *access governance and data utility*. The representative must be able to understand and facilitate these new, more technical conversations between the non-EU company and the HDAB. ### Managing New Types of Data Access and Compliance Verifications The EHDS introduces a formal process for data access permits. A researcher seeking data from a non-EU SaMD manufacturer would apply to an HDAB. The HDAB, in turn, may need to contact the manufacturer's EU representative to: * **Verify Compliance:** Confirm that the manufacturer's data governance and security practices meet EHDS standards. * **Clarify Data Scope:** Ask questions about the requested dataset to ensure it is fit for the stated research purpose and adheres to data minimization principles. * **Facilitate Secure Access:** Coordinate on the technical means for providing secure access to the pseudonymized data once a permit is granted. The representative must have a clear internal process for routing these requests, gathering the necessary information from the company's technical and legal teams, and responding to the HDAB in a timely and accurate manner. ## Assessing and Selecting an EHDS-Ready EU Representative Given this expanded scope, non-EU health tech companies must be more strategic when selecting or re-evaluating their Article 27 Representative. A generic provider with only baseline GDPR knowledge will likely be unprepared for the specific demands of the EHDS. ### A Checklist for Vetting Potential Representatives When assessing a provider, organizations should go beyond a standard GDPR compliance check. Use the following questions to gauge their readiness for the EHDS era: 1. **EHDS and Health Data Expertise:** * *Can you explain the key differences between the role of a DPA and a Health Data Access Body (HDAB)?* * *What is your understanding of the term "secondary use" of health data as defined in the EHDS proposal?* * *What experience do you have with other EU health-related regulations, such as the MDR or IVDR?* 2. **Procedural Readiness:** * *What is your documented process for handling an inquiry from an HDAB on behalf of a client?* * *How would you assist us in updating our Record of Processing Activities (ROPA) to reflect secondary data uses under EHDS?* * *Do you have staff with the technical literacy to discuss topics like data pseudonymization, interoperability standards, and secure processing environments?* 3. **Sector-Specific Experience:** * *How many of your clients are in the MedTech, SaMD, or digital health sector?* * *Can you provide anonymized case studies of complex data protection issues you have handled for health tech companies?* * *How do you stay current with evolving regulations and guidance in the European health data landscape?* 4. **Governance and Advisory Capabilities:** * *Do you provide advisory services to help clients develop internal data governance policies that are EHDS-compliant?* * *How would you advise us on drafting or amending our Data Processing Agreements (DPAs) with our own data processors to ensure they can support EHDS requirements?* A provider's ability to answer these questions with confidence and detail is a strong indicator of their preparedness to serve as an effective representative in the new health data ecosystem. ## Practical Steps for Non-EU Companies to Prepare Proactive preparation is crucial for a smooth transition. Non-EU companies should begin taking steps now to align their operations with the forthcoming EHDS requirements. 1. **Conduct a Data Governance Gap Analysis:** Review your current GDPR compliance framework against the anticipated requirements of the EHDS. Identify where your ROPA, privacy notices, and consent mechanisms need to be updated to address the legal basis and transparency requirements for secondary data use. 2. **Re-evaluate Your Current EU Representative:** Use the checklist above to engage your current representative in a conversation about their EHDS readiness. If they lack the necessary expertise in health data, it may be necessary to seek a more specialized provider. 3. **Update Key Compliance Documentation:** Begin the process of updating your ROPA to include processing activities related to potential secondary uses. Review your DPAs with cloud providers and other vendors to ensure they include clauses that permit secure data processing for EHDS-approved purposes and outline responsibilities clearly. 4. **Establish an Internal EHDS Response Team:** Designate individuals or a team within your organization (e.g., from legal, regulatory, and engineering) responsible for handling inquiries related to secondary data use. Ensure this team has a clear process for working with your EU representative to respond to HDAB requests. ## Finding and Comparing GDPR Article 27 Representative Providers Choosing the right representative is a critical strategic decision. The ideal partner is not merely a mailbox in the EU but a specialized advisor with deep expertise in both data protection law and the health technology sector. When comparing providers, prioritize those who can demonstrate a proactive understanding of the EHDS and have established processes for managing its unique requirements. Look for a provider who can act as a true partner in navigating the evolving European regulatory landscape. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/gdpr_art27_rep) and request quotes for free. ## Key EU References When navigating this topic, it is essential to refer to the official source documents and authoritative guidance. * The General Data Protection Regulation (GDPR) (Regulation (EU) 2016/679). * The official proposal for a Regulation on the European Health Data Space (EHDS). * Guidance from the European Data Protection Board (EDPB) on the roles and responsibilities under GDPR. * Relevant national data protection laws and health data regulations of the EU member states in which you operate. *** This article is for general educational purposes only and is not legal, medical, or regulatory advice. For specific legal and regulatory questions, companies should consult qualified experts and relevant European authorities. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*